Resources
- sort by:
- Relevance
- Date
- Popularity
- Bausch & Lomb-Pharmos Lenoxin agreement. (Bausch & Lomb Pharmaceuticals Inc.) (Brief Article)
- Pharmos Corporation [NASDAQ NMS: PARS] has signed a letter of intent with Bausch & Lomb Pharmaceuticals, Inc, a division of Bausch & Lomb, Inc to cooperate on the further development, production, distribution, marketing and promotion of Lenox Pharmos Corporation [NASDAQ NMS: PARS] has signed a letter...
- Research articles 1994-05-13
- Bausch & Lomb Receives Acquisition Proposal from Advanced Medical Optics for $75.00 Per Share in Cash and AMO Stock
- ROCHESTER, N.Y. -- Bausch & Lomb (NYSE:BOL) announced today that it has received from Advanced Medical Optics (NYSE:EYE) a proposal (the "AMO Proposal") to acquire 100% of the outstanding shares of Bausch & Lomb in a merger in which Bausch & Lomb's shareholders would receive, per share of Bausch &...
- Research articles 2007-07-05
- Bausch and Lomb licensed for Levi's sunglasses.
- BAUSCH & LOMB LICENSED FOR LEVI'S SUNGLASSES NEW YORK -- Bausch & Lomb has signed a licensing pact with Levi Strauss & Co. to produce a line of sunglasses under the Levi's name. The sunglasses will be introduced for sale...
- Research articles 1989-06-29
- Bausch & Lomb confirms global alliance with InSite Vision
- ROCHESTER, N.Y.--BUSINESS WIRE--July 23, 1996--Bausch & Lomb (NYSE: BOL) today announced a global alliance with InSite Vision Incorporated (NASDAQ: INSV). As part of the alliance, Bausch & Lomb will co-develop and manufacture certain glaucoma products based on InSite's proprietary DuraSiteR ophthalmic drug delivery technology. The alliance also grants Bausch...
- Research articles 1996-07-23
- BAUSCH & LOMB RETAINS CB COMMERCIAL REAL ESTATE GROUP TO MARKET GARRETT COUNTY, MD. MANUFACTURING PLANT; Unique Assignment Involves Aggressive National Marketing Campaign Targeting Firms Interested in Re-Employing Company Workers
- ROCHESTER, N.Y.--BUSINESS WIRE--Bausch & Lomb (NYSE/BOL) Global healthcare and optical products manufacturer Bausch & Lomb announced today its selection of CB Commercial Real Estate Group, the world's largest provider of diversified real estate services, as exclusive marketing company to secure the sale of its sunglass lens factory, in Oakland, Md.,...
- Research articles 1996-03-25
- Bausch & Lomb and Alcon Laboratories, Inc. Settle Eye Vitamin Patent Dispute
- ROCHESTER, N.Y. -- Bausch & Lomb (NYSE:BOL) announces a settlement agreement ending a patent dispute relating to Alcon's ICAPSR AREDS product. The agreement establishes a cross-licensing relationship that permits Alcon to continue to sell its AREDS-based nutraceutical product worldwide, and grants Bausch & Lomb global rights under one or more...
- Research articles 2005-03-18
- Bausch & Lomb eyes skin care opportunity.(INTERNATIONAL NEWS)(Bausch & Lomb Inc.)(Brief article)
- Bausch & Lomb, the French eyewear and contact lens specialist, is making a move into the skin care sector with the launch of its first range of topical eye care products. Bausch & Lomb, the French eyewear and contact lens specialist, is making a...
- Research articles 2006-04-21
- Bausch & Lomb Licenses rPlasmin from Talecris Biotherapeutics for Ophthalmic Use
- ROCHESTER, N.Y. and RESEARCH TRIANGLE PARK, N.C. -- Bausch & Lomb (NYSE:BOL) and Talecris Biotherapeutics announced today that Talecris has granted an exclusive worldwide license to Bausch & Lomb for recombinant Plasmin technology for use in ophthalmology. The companies will co-develop rPlasmin, a recombinant derivative of the human blood component...
- Research articles 2006-08-29
- Bausch & Lomb Files Preliminary Proxy Statement for Merger Agreement with Warburg Pincus
- ROCHESTER, N.Y. -- Bausch & Lomb (NYSE: BOL) has filed a preliminary proxy statement with the Securities and Exchange Commission ("SEC") for a special meeting of shareholders to be held to consider Bausch & Lomb's pending merger agreement with affiliates of Warburg Pincus. As previously announced on May 16, 2007,...
- Research articles 2007-07-10
- Bausch & Lomb Teams with Novartis Ophthalmics To Co-Promote Bausch & Lomb Retisert™
- ROCHESTER, N.Y. -- Bausch & Lomb (NYSE:BOL) and Novartis Ophthalmics, a business unit of Novartis Pharmaceutical Corp. (NYSE: NVS), will co-promote Bausch & Lomb's patented orphan drug RetisertTM fluocinolone acetonide intravitreal implant 0.59 mg, in the United States. Retisert is indicated for the treatment of chronic noninfectious posterior segment uveitis.
- Research articles 2006-02-09
- Bausch & Lomb Announces Entry Into Agreement to Sell $650 Million of Notes
- ROCHESTER, N.Y. -- In connection with the merger agreement between WP Prism Inc., Bausch & Lomb Incorporated (NYSE: BOL) ("Bausch & Lomb") and WP Prism Merger Sub Inc. ("Merger Sub") regarding the acquisition of Bausch & Lomb, Merger Sub today announced that it has entered into an agreement to sell...
- Research articles 2007-10-16
- Bausch & Lomb Clarifies Reporting of Fusarium Keratitis Cases to FDA
- ROCHESTER, N.Y. -- Bausch & Lomb wishes to clarify information contained in media reports about the U.S. Food and Drug Administration's inspection of Bausch & Lomb's manufacturing plant and distribution facility in Greenville, S.C., that erroneously suggest that Bausch & Lomb withheld from FDA information the Company received about Fusarium...
- Research articles 2006-05-17
- Control Delivery Systems Announces Increased Funding for Collaboration With Bausch & Lomb On Sight-Threatening Eye Diseases
- Business/Technology Editors & Health/Medical Writers BioWire2K WATERTOWN, Mass.--BW HealthWire--May 7, 2002 Control Delivery Systems, Inc. CDS announced today that CDS and Bausch & Lomb have formalized an amended budget under their license and development agreement reflecting an increase in Bausch & Lomb's funding to $206 million through...
- Research articles 2002-05-07
- Clear is dear to mouthwash marketers. (Bausch and Lomb Inc. and DEP Corp.'s mouthwashes packaging)(includes related article)
- Bausch & Lomb's Clear Choice[TM] and Dep's Crystal Fresh Lavoris[R] are banking on consumer demand for clarity in products from soft drinks to dishwashing soap to stimulate sales of their newly introduced mouthwashes. Not only are both offering Bausch & Lomb's Clear Choice[TM] and...
- Research articles 1993-03-01
- In response to summary class-action notice in Alabama contact lens case, Bausch & Lomb reaffirms position that lawsuit is without merit
- ROCHESTER, NY--BUSINESS WIRE--March 31, 1995--In response to the class action "notification" plan that goes into effect today for some past purchasers of Bausch & Lomb contact lenses, Carl E. Sassano, president of the company's Contact Lens Division, said that the lawsuit "is totally without merit and Bausch & Lomb...
- Research articles 1995-03-31
- Lerach Coughlin Stoia Geller Rudman & Robbins LLP Announces Expanded Class Period in Class Action Lawsuit against Bausch & Lomb, Inc
- NEW YORK -- Lerach Coughlin Stoia Geller Rudman & Robbins LLP ("Lerach Coughlin") (http://www.lerachlaw.com/cases/bauschandlomb/) today announced that an amended complaint has been filed in the United States District Court for the Southern District of New York on behalf of purchasers of Bausch & Lomb, Inc. ("Bausch & Lomb") (NYSE:BOL) publicly...
- Research articles 2006-05-05
- Bausch & Lomb Commences Exchange Offer For Convertible Securities
- ROCHESTER, N.Y. -- Bausch & Lomb (NYSE: BOL) announced today that it is offering to exchange up to $160 million aggregate principal amount of its outstanding Floating Rate Convertible Senior Notes due 2023 (the "Old Notes") for an equal amount of its 2004 Senior Convertible Securities due 2023 (the "New...
- Research articles 2004-11-15
- Bausch & Lomb Second-Quarter Profits Rise On Double-Digit Sales Increase
- Business Editors ROCHESTER, N.Y.--BUSINESS WIRE--July 25, 2002--Bausch & Lomb (NYSE:BOL) - Second-quarter revenues of $458.4 million increase 14% - Comparable-basis EPS of $0.40 improve $0.19 - ...
- Research articles 2002-07-25
- Bausch & Lomb Investor Conference Call - Research and Markets offers a brief of 'Bausch & Lomb' Conference Call
- DUBLIN, Ireland -- The Bausch & Lomb (NYSE:BOL) Corporate Conference Call took place on 15-May-06 2:00pm ET.
- Research articles 2006-05-15
- Jay T. Holmes announces plan to retire from Bausch & Lomb
- ROCHESTER, N.Y.--BUSINESS WIRE--March 22, 1996--Bausch & Lomb (NYSE/BOL) Jay T. Holmes, executive vice president and chief administrative officer of Bausch & Lomb today announced his intention to retire from the company coincident with the annual meeting on May 10, 1996. He has also chosen not to stand for reelection...
- Research articles 1996-03-22
- << Previous
- page 1 of 32
- Next >>
